5 Stocks with Biggest Upside Potential According to Analysts

2. Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Number of Hedge Fund Holders: 22

Upside Potential as of July 20: 242.34%

Brisbane, California-based Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is a clinical-stage biopharmaceutical company developing targeted therapies for patients of all ages with life-threatening diseases. Its lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor.

On June 12, Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) announced the close of its previously announced public offering of its common stock at a public offering price of $13.00 per share to raise gross proceeds of nearly $172.5 million.

On June 5, HC Wainwright & Co. raised the price target on Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares to $50 from $45 and maintained a ‘Buy’ rating for the shares. The target price represents a potential upside of nearly 321% based on the share price on July 20.